Clarius Group LLC Buys New Shares in Haleon plc (NYSE:HLN)

Clarius Group LLC purchased a new stake in shares of Haleon plc (NYSE:HLN) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 58,527 shares of the company’s stock, valued at approximately $558,000.

Several other large investors have also recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Sculptor Capital LP increased its holdings in Haleon by 67.8% in the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after buying an additional 3,592,000 shares during the period. Clearbridge Investments LLC raised its stake in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after buying an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Haleon by 49.9% during the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after acquiring an additional 3,046,841 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Up 0.5 %

Shares of NYSE HLN opened at $9.24 on Monday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $41.80 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.29. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The firm’s 50-day simple moving average is $9.54 and its 200 day simple moving average is $9.71.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.